Overview
Kidney cancer also called renal cancer is a disease in which
kidney cells become malignant (cancerous) and grows out of control, forming a
tumor. Symptoms include blood in urine, loss of appetite, fever that lasts for
weeks, extreme fatigue, and anemia, shortness of breath and bone pain.
Treatment includes surgery, radiation therapy and chemotherapy.
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1555345-kidney-cancer-renal-cell-cancer-pipeline-review-h1-2017
Report
Highlights
The Pharmaceutical and Healthcare latest pipeline guide
Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2017, provides
comprehensive information on the therapeutics under development for Kidney
Cancer (Renal Cell Cancer) (Oncology), complete with analysis by stage of
development, drug target, mechanism of action (MoA), route of administration
(RoA) and molecule type. The guide covers the descriptive pharmacological
action of the therapeutics, its complete research and development history and
latest news and press releases.
The Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline
guide also reviews of key players involved in therapeutic development for
Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued
projects. Similarly, the Universities portfolio in Phase II, Phase I and
Preclinical stages comprises 12, 5 and 11 molecules, respectively.
Kidney Cancer (Renal Cell Cancer) (Oncology) pipeline guide
helps in identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage. Additionally, various dynamic
tracking processes ensure that the most recent developments are captured on a
real time basis.
Major Scope of the report:
- The pipeline guide provides a snapshot of the global
therapeutic landscape of Kidney Cancer (Renal Cell Cancer) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Kidney Cancer (Renal Cell Cancer) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide reviews pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Kidney Cancer (Renal Cell Cancer) (Oncology) therapeutics and enlists all their major and minor projects.
Table of Contents
Table of Contents 2
Introduction 9
Kidney Cancer (Renal Cell Cancer) - Overview 10
Kidney Cancer (Renal Cell Cancer) - Therapeutics Development 11
Kidney Cancer (Renal Cell Cancer) - Therapeutics Assessment 48
Kidney Cancer (Renal Cell Cancer) - Companies Involved in Therapeutics Development 72
Kidney Cancer (Renal Cell Cancer) - Drug Profiles 157
Kidney Cancer (Renal Cell Cancer) - Dormant Projects 1233
Kidney Cancer (Renal Cell Cancer) - Discontinued Products 1246
Kidney Cancer (Renal Cell Cancer) - Product Development Milestones 1249
Appendix 1265
Introduction 9
Kidney Cancer (Renal Cell Cancer) - Overview 10
Kidney Cancer (Renal Cell Cancer) - Therapeutics Development 11
Kidney Cancer (Renal Cell Cancer) - Therapeutics Assessment 48
Kidney Cancer (Renal Cell Cancer) - Companies Involved in Therapeutics Development 72
Kidney Cancer (Renal Cell Cancer) - Drug Profiles 157
Kidney Cancer (Renal Cell Cancer) - Dormant Projects 1233
Kidney Cancer (Renal Cell Cancer) - Discontinued Products 1246
Kidney Cancer (Renal Cell Cancer) - Product Development Milestones 1249
Appendix 1265
List of Tables
Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Number of Products under Development for Kidney Cancer (Renal Cell Cancer), H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..3), H1 2017
Continued
For Detailed Reading Please visit @ https://www.wiseguyreports.com/reports/1555345-kidney-cancer-renal-cell-cancer-pipeline-review-h1-2017
About Us
Wise Guy
Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium
progressive statistical surveying, market research reports, analysis &
forecast data for industries and governments around the globe. Wise Guy Reports
understand how essential statistical surveying information is for your
organization or association. Therefore, we have associated with the top
publishers and research firms all specialized in specific domains, ensuring you
will receive the most reliable and up to date research data available.
Contact Us:
NORAH TRENT
Partner
Relations & Marketing Manager
Ph:
+1-646-845-9349 (US)
Ph: +44 208
133 9349 (UK)
No comments:
Post a Comment